Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Gram-positive infections
- Focus Adverse reactions
- Sponsors The Medicines Company
- 01 Nov 2016 Results published in the Clinical Pharmacology in Drug Development
- 23 Jan 2013 New trial record